Stay updated on Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.

Latest updates to the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.2; there are no visible changes to study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded metadata date fields to the Study Record Dates, including Last Update Posted (Estimated), with several future study dates listed. Removed a government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check42 days agoChange DetectedThe changes seem to be formatting/layout adjustments with no modification to core study details such as inclusion criteria, primary/secondary outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference4%

- Check78 days agoChange DetectedUpdate: version upgraded to v3.1.0 and new contact details added (phone and three emails); previous version v3.0.2 removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now shows revision v3.0.2 and removes v3.0.1 and the Back to Top element. Overall, this is a minor update focused on versioning and navigation.SummaryDifference0.2%

Stay in the know with updates to Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.